Navigation Links
Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Date:4/28/2009

up to be extremely interesting in light of recent UK directives from the Department of Health concerning mandatory MRSA screening for all elective admissions and other developments in infection control across Europe," said Dr. David Persing, M.D., Ph.D., Cepheid's Chief Medical and Technology Officer. "Additionally, we expect to showcase our Xpert(R) MTB/RIF test for Mycobacterium tuberculosis - a product that, in my opinion, is one of the most important diagnostic developments to have occurred in many years."

Xpert MTB/RIF not only detects the presence of TB organism directly from sputum in less than two hours, but also identifies whether the strain is resistant to rifampicin, a commonly used first-line drug for treatment of the disease. Many studies have shown that rifampicin resistance is a reliable surrogate marker of strains that are multidrug-resistant TB (MDR-TB), and the frequency of MDR-TB is increasing in the EU. The test is expected to enable clinicians to dramatically improve the way they initially manage tuberculosis by helping them to make the right therapeutic decision on the first day of the initial patient encounter.

Cepheid currently offers European clinicians a broad menu of on-demand molecular diagnostic tests designed to enhance patient management. The full menu of CE IVD tests expected to be available for demonstration at booth #611 include:

  • Xpert(R) MTB/RIF
    • Diagnostic test for the simultaneous detection of Mycobacterium tuberculosis and resistance to rifampicin
  • Xpert(R) C. difficile
    • Diagnostic test for Clostridium difficile infection
  • Xpert(R) vanA/vanB
    • Detection of vanA and vanB, the genes most associated with hospital-acquired vancomycin-resistant enterococci (VRE)
    '/>"/>

SOURCE Cepheid
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cepheid Reports 2009 First Quarter Results
2. Cepheid Schedules Fiscal 2009 First Quarter Financial Results Announcement and Webcast
3. Cepheid Announces New Diagnostic Technology to Aid World Efforts in Halting the Spread of Mycobacterium Tuberculosis (TB)
4. Cepheid Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
5. Cepheid to Webcast Upcoming Financial Presentations
6. Cepheid Accelerates Direct Sales Channel in UK With Pending Acquisition of Medical Distributor Stretton Scientific
7. Cepheid Reports Third Quarter Revenue of $44.9 Million
8. Results of United Kingdom MRSA Surveillance Program Using Cepheid GeneXpert(R) System Demonstrate Benefits of Rapid Testing
9. Cepheid Molecular Diagnostic Test for MRSA and S. aureus Categorized Moderate Complexity by FDA
10. Cepheid Schedules Fiscal 2008 Third Quarter Financial Results Announcement and Webcast
11. Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... CLARA, Calif. , July 29, 2014 /PRNewswire-iReach/ ... services agreement with FORMA Therapeutics, Inc., to provide ... and proprietary fragment-based lead discovery platform for novel ... really excited about the opportunity to work with ... fields of epigenetics and protein homeostasis. FORMA Therapeutics, ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 July ... vaccine pioneer in the biotechnology industry, announced that ... Coast Securities, Inc. to explore financing opportunities that ... technology, a breakthrough vaccine platform with the potential ... The company exclusively licensed the well-established LAMP platform ...
(Date:7/29/2014)... Quorum Review IRB, the industry ... accreditation by the International Association of Six ... Sigma Deployment Program. The citation recognizes robust organizational ... Quorum’s Lean Six Sigma program was evaluated by ... The designation is a public statement of excellence ...
(Date:7/29/2014)... Boston, MA (PRWEB) July 29, 2014 ... the Library of Congress was recently awarded to Juliana ... in Stoneham, MA, for their project, “From an Egg, ... from among 3,000 final entries for the National History ... more than 300 historians and educators in Washington, D.C. ...
Breaking Biology Technology:Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 2Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 3In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 3
... Incorporated (Nasdaq: ARAY ), a global leader in ... results for its second quarter of fiscal 2011, ended December ... closes. A conference call to review the results ... be hosted by Euan S. Thomson, Ph.D., president and chief ...
... Registration is now open for StemCONN 2011. ... in stem cell research, will take place Tuesday, March ... session) and the UConn Health Center (commercial session and ... at http://stemconn.org/ . StemCONN 2011 will ...
... Md., Jan. 13, 2011 Celsion Corporation (Nasdaq: ... to the development and commercialization of innovative oncology drugs, ... securities purchase agreement with a select group of institutional ... to sell 5,000 shares of 8% redeemable convertible preferred ...
Cached Biology Technology:Accuray Incorporated to Report Financial Results for Second Quarter of Fiscal 2011 2Celsion Corporation Announces Convertible Preferred Stock Financing and Amended License Agreement for Aggregate Gross Proceeds of up to $9 Million 2Celsion Corporation Announces Convertible Preferred Stock Financing and Amended License Agreement for Aggregate Gross Proceeds of up to $9 Million 3Celsion Corporation Announces Convertible Preferred Stock Financing and Amended License Agreement for Aggregate Gross Proceeds of up to $9 Million 4
(Date:7/29/2014)... (UM SOD) and Medicine (UM SOM) jointly announced ... million grant award from the National Institute of ... Institutes of Health to study the causes, prevention ... which renews a previous $12 million five-year NIAID-funded ... research by studying chlamydial and gonorrheal diseases as ...
(Date:7/29/2014)... to go and almost 2500 registered participants, the final ... The event, a joint venture between the Federation of ... for Biochemistry and Molecular Biology (SFBBM), will take place ... the Palais des Congrs in Paris, France. , The ... life sciences in Europe this year. It features more ...
(Date:7/29/2014)... it affects 1 in 100,000 people characterized by ... its cause remains unknown, a new study by a team ... Bonn in Germany and other European institutions confirms for the ... published on 6 July in Nature Genetics , is ... we swallow, a sphincter in the lower esophagus opens, allowing ...
Breaking Biology News(10 mins):University of Maryland Schools of Dentistry and Medicine receive NIH grant 2University of Maryland Schools of Dentistry and Medicine receive NIH grant 3University of Maryland Schools of Dentistry and Medicine receive NIH grant 4Counting down to FEBS-EMBO 2014 in Paris, France 2Mysterious esophagus disease is autoimmune after all 2
... Entomological Society of America (ESA) invites scientists to submit ... which will be held in Knoxville, Tennessee, November 11-14, ... This year,s theme is "A Global Society for ... reflect this theme, if possible. The deadline for ...
... Oilsands development uses a vast amount of water and ... the toxins and metals leftover from extracting and upgrading ... a lightening rod for controversy and a significant risk ... at the University of Calgary and engineers at the ...
... Hay fever (runny nose, sneezing, itchy eyes) is caused by ... These tiny grains bring misery to sufferers through spring and ... weather reports to help sufferers prepare. However new research published ... Allergy shows that, regardless of medication and other allergies, ...
Cached Biology News:Researchers develop new method of cleaning toxins from the oilsands 2Get ready for spring - hay fever worse in spring than summer 2
Purified Mouse anti-Hu LAT (pY226) Storage Temperature: Refrigerate(2 to 8C)...
Tris-EDTA Buffer Solution, 1X, pH 8.0, sterile, Molecular Biology Grade...
... the most comprehensive, cost-effective solution to ... incorporated unprecedented quality into both our ... proven detection chemistries and antibodies that ... protocol. It also includes our competitively ...
...
Biology Products: